Novo Nordisk (NVO)
(Delayed Data from NYSE)
$136.97 USD
+0.09 (0.07%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $136.93 -0.04 (-0.03%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$136.97 USD
+0.09 (0.07%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $136.93 -0.04 (-0.03%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth F Momentum D VGM
Zacks News
Novo Nordisk (NVO) Beats on Q1 Earnings, Revenues Down Y/Y
by Zacks Equity Research
Novo Nordisk A/S (NVO) reported first-quarter 2017 earnings of 58 cents per American Depositary Receipt (ADR) beating the Zacks Consensus Estimate of 53 cents by 9.4%.
6 FDA Events to Watch Out for in May 2017
by Arpita Dutt
Here is a look at a few important regulatory events scheduled for the month of May including the FDA's decision regarding the label expansion of Merck's (MRK) Keytruda.
Merck's Bid to Add Cardiovascular Data on Januvia Label Fails
by Zacks Equity Research
Merck announced that the FDA has denied approval to include cardiovascular outcomes data on the labels of its diabetes drug, Januvia (sitagliptin) and other medicines containing Januvia.
Novo Nordisk: Positive CHMP Nod for Tresiba Label Expansion
by Zacks Equity Research
Novo Nordisk A/S (NVO) announced that the Committee for Medicinal Products for Human Use (CHMP), has issued a positive opinion suggesting an update to the label for Tresiba (insulin degludec) to include data from the SWITCH studies.
Orexigen Inks Commercialization Deal for Contrave, Stock Up
by Zacks Equity Research
Orexigen Therapeutics, Inc.'s (OREX) announced that it has entered into a commercialization and distributorship agreement with Italian pharmaceutical company, Bruno Farmaceutici, for its obesity drug, Contrave.
Novo Nordisk's Diabetes Unit Strong; Generic Pressure Stays
by Zacks Equity Research
We issued an updated research report on Novo Nordisk (NVO) on Mar 9, 2017.
Merck/Pfizer's Diabetes Drug Accepted for Review by FDA, EMA
by Zacks Equity Research
Merck & Co., Inc. (MRK) and partner Pfizer, Inc. (PFE) announced that the FDA has accepted its new drug applications (NDA) for ertugliflozin as a monotherapy as well as two fixed-dose combination tablets.
Zacks Industry Outlook Highlights: Sanofi, AstraZeneca, Novo Nordisk, Gilead Sciences and Valeant Pharmaceuticals International
by Zacks Equity Research
Zacks Industry Outlook Highlights: Sanofi, AstraZeneca, Novo Nordisk, Gilead Sciences and Valeant Pharmaceuticals International
Top Analyst Reports for Priceline, Schwab & NextEera Energy
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Priceline (PCLN), NextEra Energy (NEE) and Schwab (SCHW).
Novo Nordisk Inks Diabetes Deal with University of Oxford
by Zacks Equity Research
Novo Nordisk A/S (NVO) and University of Oxford announced a landmark research collaboration for the treatment of type II diabetes.
Novo Nordisk (NVO) Fiasp Gets EU Nod for Diabetes in Adults
by Zacks Equity Research
Novo Nordisk (NVO) announced that its fast-acting insulin aspart, Fiasp, has been approved in the EU for the treatment of diabetes in adults.
Lilly Jardiance Family Diabetes Drugs' Label to be Updated
by Zacks Equity Research
Eli Lilly & Company (LLY) recently announced that the FDA has approved the inclusion of data from the EMPA-REG OUTCOME study on the labels of three type 2 diabetes medicines belonging to the Jardiance family ??? Synjardy, Synjardy XR and Glyxambi.
New Strong Sell Stocks for December 27th
by Indradip Ghosh
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Lilly Stock Surges on Robust 2017 View; Launches Basaglar
by Zacks Equity Research
Eli Lilly and Company (LLY) issued a better-than-expected financial guidance for 2017, alleviating investor concern to a large extent.
Eli Lilly (LLY) to Offer Discount on Insulin from January
by Zacks Equity Research
Eli Lilly (LLY) announced that the company will offer access to its insulin products at discounted prices, starting Jan 2017.
Lilly (LLY) Gets FDA Nod for Once-Daily Version of Synjardy
by Zacks Equity Research
Eli Lilly and Company (LLY) announced the FDA approval of an extended-release formulation of its type II diabetes prescription drug Synjardy.
Should Biotech Investors Worry About Donald Trump?
by Arpita Dutt
It looks like biotech investors may have heaved a sigh of relief a bit too early when Presidential election results were announced last month.
Lilly: Jardiance Label to Add Cardiovascular Indication
by Zacks Equity Research
Eli Lilly & Company (LLY) recently announced that the FDA has approved the inclusion of cardiovascular (CV) risk reduction data from the EMPA-REG OUTCOME study on its type II diabetes drug Jardiance's (SGLT-2 inhibitor) label.
Novo Nordisk Files Regulatory Application for Semaglutide
by Zacks Equity Research
Novo Nordisk (NVO) submitted regulatory application for semaglutide in both the U.S. and the EU for the treatment of adults with type II diabetes.
Novo Nordisk's Tresiba Shows Safe Cardiovascular Profile
by Zacks Equity Research
Novo Nordisk (NVO) announced headline results from the DEVOTE study that confirmed the cardiovascular safety of Tresiba, in comparison to Sanofi???s (SNY) Lantus.
Pharma Industry Stock Outlook - March 2016
by Arpita Dutt
Looking at consensus earnings expectations, the Medical sector, which had performed well in 2015, is expected to see earnings growth of 0.7% and revenue growth of 7.7% in Q1.
Pharma Industry Stock Outlook - March 2016
by Arpita Dutt
Looking at consensus earnings expectations, the Medical sector, which had performed well in 2015, is expected to see earnings growth of 0.7% and revenue growth of 7.7% in Q1.